Evidence map›Paper›PMID 32669601›Full record

ArticleNature communications2020

Sequential role of RAD51 paralog complexes in replication fork remodeling and restart.

Matteo Berti, Federico Teloni, Sofija Mijic, Sebastian Ursich, Jevgenij Fuchs, Maria Dilia Palumbieri, Jana Krietsch, Jonas A Schmid, Edwige B Garcin, Stéphanie Gon and 3 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 1 pooled it
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 1 synthesis or guideline pooled it, 93 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Impact of germlineMolecular therapy. Oncology · 2026
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Combination of PARP and KRASNature communications · 2026
    Article
  19. Article
  20. Review

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 3 countries.

Matteo Berti *Institute of Molecular Cancer Research, University of Zurich, Winterthurerstrasse 190, 8057, Zurich, Switzerland.
Federico Teloni *Department of Molecular Mechanisms of Disease, University of Zurich, Winterthurerstrasse 190, 8057, Zurich, Switzerland.ORCID http://orcid.org/0000-0003-0953-8010
Sofija MijicInstitute of Molecular Cancer Research, University of Zurich, Winterthurerstrasse 190, 8057, Zurich, Switzerland.ORCID http://orcid.org/0000-0001-5325-1901
Sebastian UrsichInstitute of Molecular Cancer Research, University of Zurich, Winterthurerstrasse 190, 8057, Zurich, Switzerland.
Jevgenij FuchsInstitute of Molecular Cancer Research, University of Zurich, Winterthurerstrasse 190, 8057, Zurich, Switzerland.ORCID http://orcid.org/0000-0002-6645-5433
Maria Dilia PalumbieriInstitute of Molecular Cancer Research, University of Zurich, Winterthurerstrasse 190, 8057, Zurich, Switzerland.
Jana KrietschInstitute of Molecular Cancer Research, University of Zurich, Winterthurerstrasse 190, 8057, Zurich, Switzerland.
Jonas A SchmidInstitute of Molecular Cancer Research, University of Zurich, Winterthurerstrasse 190, 8057, Zurich, Switzerland.
Edwige B GarcinCancer Research Center of Marseille; CNRS; Inserm; Institut Paoli-Calmettes; Aix-Marseille Université, 27 Bd Leï Roure, CS 30059, 13273, Marseille, France.ORCID http://orcid.org/0000-0002-0533-6940
Stéphanie GonCancer Research Center of Marseille; CNRS; Inserm; Institut Paoli-Calmettes; Aix-Marseille Université, 27 Bd Leï Roure, CS 30059, 13273, Marseille, France.ORCID http://orcid.org/0000-0002-1513-5018
Mauro ModestiCancer Research Center of Marseille; CNRS; Inserm; Institut Paoli-Calmettes; Aix-Marseille Université, 27 Bd Leï Roure, CS 30059, 13273, Marseille, France.ORCID http://orcid.org/0000-0002-4964-331X
Matthias AltmeyerDepartment of Molecular Mechanisms of Disease, University of Zurich, Winterthurerstrasse 190, 8057, Zurich, Switzerland. matthias.altmeyer@dmmd.uzh.ch.ORCID http://orcid.org/0000-0003-3780-1170
Massimo LopesInstitute of Molecular Cancer Research, University of Zurich, Winterthurerstrasse 190, 8057, Zurich, Switzerland. lopes@imcr.uzh.ch.ORCID http://orcid.org/0000-0003-3847-8133
University of Zurich · CHCentre National de la Recherche Scientifique · FRZHAW Zurich University of Applied Sciences · CH

Funding

European Research Council 714326
6 · The paper itself

Abstract

Homologous recombination (HR) factors were recently implicated in DNA replication fork remodeling and protection. While maintaining genome stability, HR-mediated fork remodeling promotes cancer chemoresistance, by as-yet elusive mechanisms. Five HR cofactors - the RAD51 paralogs RAD51B, RAD51C, RAD51D, XRCC2 and XRCC3 - recently emerged as crucial tumor suppressors. Albeit extensively characterized in DNA repair, their role in replication has not been addressed systematically. Here, we identify all RAD51 paralogs while screening for modulators of RAD51 recombinase upon replication stress. Single-molecule analysis of fork progression and architecture in isogenic cellular systems shows that the BCDX2 subcomplex restrains fork progression upon stress, promoting fork reversal. Accordingly, BCDX2 primes unscheduled degradation of reversed forks in BRCA2-defective cells, boosting genomic instability. Conversely, the CX3 subcomplex is dispensable for fork reversal, but mediates efficient restart of reversed forks. We propose that RAD51 paralogs sequentially orchestrate clinically relevant transactions at replication forks, cooperatively promoting fork remodeling and restart.

Indexed as

DNA ReplicationBRCA2 ProteinCell Line, TumorChromosomesChromosome StructuresDNA-Binding ProteinsDNA DamageDNA RepairGenomic InstabilityHomologous RecombinationHumansMicroscopyMutagensMutationOsteosarcomaRad51 RecombinaseBRCA2 ProteinBRCA2 protein, humanDNA-Binding ProteinsMutagensRAD51B protein, humanRAD51C protein, humanRAD51D protein, humanRAD51 protein, humanRad51 RecombinaseRNA, Small InterferingX-ray repair cross complementing protein 3XRCC2 protein, human

Identifiers

PMID32669601
PMCPMC7363682
OpenAlexW3043743907

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.